trending Market Intelligence /marketintelligence/en/news-insights/trending/Bi_RZyFzzi7g_LaVzq_pSw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

Pfizer Inc. has joined with San Diego-based private biotech eFFECTOR Therapeutics Inc. to develop small-molecule inhibitors of a certain protein that is activated in a number of human cancers.

The collaboration will focus on the development of small-molecule inhibitors of eukaryotic initiation factor 4E, a protein that resists certain cancer treatments and is linked to poor prediction of the disease.

Under the exclusive worldwide license and collaboration agreement, Pfizer will pay eFFECTOR $15 million upfront and up to an additional $492 million in potential development and sales milestone payments.

Additionally, eFFECTOR will receive royalties on sales of any products from the program that reaches the commercialization stage.